- New ETFs
- Bond ETFs
- Currency ETFs
- Emerging Market ETFs
- Commodity ETFs
- Broad U.S. Equity ETFs
- Sector ETFs
- Specialty ETFs
BioMarin Pharmaceutical, Inc. (BMRN) One Of Top Picks Of 2010
Recent Articles by Ed Liston
- Regulators Failed During The Financial Crisis Due To Complacency; Alan Greenspan (JPM)
- Court Asks Fed To Disclose Records Of $2 Trillion U.S. Loan Program Launched After Lehman Collapse (OPY)
- Boeing (BA) Plans To Raise Production Of 777s And 747s Sooner-Than-Expected
- Metabolix, Inc. (MBLX) Maintains Market Weight Rating
- Pressure Mounts On EU To Create A System To Handle Failure Of Large Banks
Analyst Color
- General Growth Properties (GGP) Is Back In Favor
- JPMorgan Raises Its Estimates For Intel (INTC, JPM)
- Metabolix, Inc. (MBLX) Maintains Market Weight Rating
- Brean Murray Carret & Co. Believes Pullback In Bruker Represents Opportunity (BRKR)
- EnerNOC, Inc. (ENOC) Maintains Overweight Rating
Company News
- Tiffany Reports Earnings Monday Morning (TIF)
- Carl Icahn Makes Hostile Takeover Bid For Lions Gate Entertainment (LGF)
- Ex-Cadbury Executive To Head Kraft’s Confectionery Unit (KFT)
- Morningstar Acquires Realpoint LLC (MORN)
- Pfizer Eyes German Drug Maker Stada (PFE, TEVA)
Markets
- Carter Worth Says Best Buy Losing Momentum (BBY)
- Icahn Offers To Purchase All Outstanding Shares Of Lions Gate (LGF)
- Biotech Stock Mailbag: Generex (PFE, MNKD)
- VIX Lurching Higher Off Historical Support On Greece Worries (VIX)
- Apple Is Hoping To Have Apps For That (AAPL)
Analyst Ratings
Posted on 02/05/10 at 9:58am by Ed Liston
Analysts Salveen J. Kochnover and Brent Kelly at Collins Stewart have released an update on BioMarin Pharmaceutical, Inc. (NASDAQ: BMRN). Analysts have a Buy rating for the company.
According to analysts, the company remains one of their top picks for 2010 due to an attractive pipeline, strong top-line product growth, and a strong cash position.
The company announced positive preliminary 24-week data from the GALNS P 1/2 study in MPS IV, yesterday. The company also gave details on the intended acquisition of privately held LEAD Therapeutics.
The acquisition will provide BioMarin rights to LT-673, a pre-clinical PARP inhibitor for treatment of rare, genetically defined cancer.
Analysts are encouraged by the GALNS’ demonstrated functional improvements in patients. However, analysts are not convinced about the benefits from the LEAD acquisition. Analysts have a price target of $22 for BioMarin Pharmaceutical, Inc.
Bookmark/Search this post with:
Related Articles
Today's Trading Ideas
Featured Articles
Related News from the Stock Market
- BioMarin to Present at the Barclays Capital Global Healthcare Conference
- Stocks That Created New 52-Week Highs (BGCP, BIIB, BMRN, BJRI, BRCM)
- Top Takeover Targets In The Biotechnology Sector This Year (VRTX, AUXL, CELG, ITMN, GENZ)
- BioMarin to Present at the Cowen and Company 30th Annual Health Care Conference
- BioMarin Supports Observance of Rare Disease Day February 28
There are 0 comments
Please note that comments may take up to one hour before they get published on the site. Please check back later to see your comments.
Post new comment
Receive Benzinga's Best 2010 Stock Idea!
